Optimization of reactive arthritis treatment using systemic enzyme therapy

Mazurov V.I., Lila A.M.

Medical Academy of Postgraduate Studies, St. Petersburg, Russia.

Int. J. Immunotherapy 2001, Vol. XVII, No. 2/3/4, pp. 125-128  - ISSN 0255-9625

218 K/375 (19-05-3)

Summary: We studied 28 cases of the genitourinary variant of chlamydial reactive arthritis (ReA). All patients wore divided into two groups. Group 1 included 17 patients who received antibacterial therapy (Tarivid^®, Sumamed^®), nonsteroid antiinflammatory drugs (NSAIDs) (diclofenac, Movalis^®) and Phlogenzym^®. Group 2 included 11 patients who received antibiotics and NSAIDs. We dynamically evaluated general, biochemical and immunological blood parameters including the patients' interferon profile. The results showed that ReA patients included in group 1 who received complex therapy with Phlogenzym^® showed faster relief of manifestations of joint lesion syndrome, a decrease in laboratory evidence of disease activity and normalization of interferon profile. In addition, the effect of antibacterial drugs was improved and chlamydia elimination was more effective.